EUVIMEDEUVIMED entdecken
Crossref

Chimeric peptides targeting the receptor-binding domain of SARS-CoV-2 variants inhibit ACE2 interaction

Pisit Ubonsri, Jiraporn Panmanee, Ittipat Meewan, Promsin Masrinoul, Jukrapun Komaikul, Surapon Piboonpocanun

Asian Pacific Journal of Allergy and Immunology · 2025

DOI: 10.12932/ap-030424-1833 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2025. Verfasst von Pisit Ubonsri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom, Thailand. Hauptthemen laut MEDLINE: SARS-CoV-2, Angiotensin-Converting Enzyme 2, Spike Glycoprotein, Coronavirus, COVID-19.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein is pivotal in facilitating viral entry and serves as a major target for vaccine development and therapeutics. Despite undergoing mutations aimed at evading host immunity, certain regions within the RBD remain conserved. OBJECTIVE: This study aimed to identify peptides capable of interacting with these conserved regions of the RBD across various variants and assess their neutralization potential. METHODS: The PhD-12 phage display library underwent screening to identify phages binding to the RBD. Selected phage clones were examined for binding to the RBD of multiple variants, including 2019-nCoV, Delta (B.1.617.2), Omicron (B.1.1.529), and XBB. Peptides, expressed as chimeric constructs, were tested for their binding to the RBD, the Omicron trimeric S, inactivated SARS-CoV-2 virus, and neutralizing activity. The binding sites were analyzed using Molecular Docking. RESULTS: Two selected phage clones displayed peptides binding to the RBD of multiple variants. Chimeric T hioredoxin-peptides (Trx-RB9 and Trx-RB10) exhibited binding to both inactivated SARS-CoV-2 and the Omicron trimeric S, with half-maximum effective concentrations (EC50 ) values of 111.9 and 360.2 nM, respectively. Molecular docking revealed distinct binding sites within the RBD of the Omicron trimeric S for both Trx-RB9 and Trx-RB10. A mixture of Trx-RB9 and Trx-RB10 inhibited 78% of the binding of recombinant human ACE2 to the Omicron trimeric S. CONCLUSIONS: The chimeric Trx-RB9 and Trx-RB10 peptides bind to the RBD of SARS-CoV-2 variants and inhibit the binding of ACE2 to the RBD of the Omicron trimeric S.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Angiotensin-Converting Enzyme 2Spike Glycoprotein, CoronavirusCOVID-19PeptidesHumansMolecular Docking SimulationProtein BindingPeptide LibraryBinding SitesProtein Domains

Substanzen

Angiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2 protein, humanPeptidesPeptide Library

Autor:innen und Institutionen

  • Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom, Thailand.

Zitieren

APA

Ubonsri, P., Panmanee, J., Meewan, I., Masrinoul, P., Komaikul, J., & Piboonpocanun, S. (2025). Chimeric peptides targeting the receptor-binding domain of SARS-CoV-2 variants inhibit ACE2 interaction. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-030424-1833

Vancouver

Ubonsri P, Panmanee J, Meewan I, Masrinoul P, Komaikul J, Piboonpocanun S. Chimeric peptides targeting the receptor-binding domain of SARS-CoV-2 variants inhibit ACE2 interaction. Asian Pacific Journal of Allergy and Immunology. 2025. doi:10.12932/ap-030424-1833

BibTeX
@article{Ubonsri2025,
  author = {Ubonsri, Pisit and Panmanee, Jiraporn and Meewan, Ittipat and Masrinoul, Promsin and Komaikul, Jukrapun and Piboonpocanun, Surapon},
  title = {Chimeric peptides targeting the receptor-binding domain of SARS-CoV-2 variants inhibit ACE2 interaction},
  journal = {Asian Pacific Journal of Allergy and Immunology},
  year = {2025},
  doi = {10.12932/ap-030424-1833}
}
Kostenlos starten →